Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples

Abstract Effect estimates from randomized trials and observational studies might not be directly comparable because of differences in study design, other than randomization, and in data analysis. We propose a 3-step procedure to facilitate meaningful comparisons of effect estimates from randomized t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of epidemiology 2019-08, Vol.188 (8), p.1569-1577
Hauptverfasser: Lodi, Sara, Phillips, Andrew, Lundgren, Jens, Logan, Roger, Sharma, Shweta, Cole, Stephen R, Babiker, Abdel, Law, Matthew, Chu, Haitao, Byrne, Dana, Horban, Andrzej, Sterne, Jonathan A C, Porter, Kholoud, Sabin, Caroline, Costagliola, Dominique, Abgrall, Sophie, Gill, John, Touloumi, Giota, Pacheco, Antonio G, van Sighem, Ard, Reiss, Peter, Bucher, Heiner C, Montoliu Giménez, Alexandra, Jarrin, Inmaculada, Wittkop, Linda, Meyer, Laurence, Perez-Hoyos, Santiago, Justice, Amy, Neaton, James D, Hernán, Miguel A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Effect estimates from randomized trials and observational studies might not be directly comparable because of differences in study design, other than randomization, and in data analysis. We propose a 3-step procedure to facilitate meaningful comparisons of effect estimates from randomized trials and observational studies: 1) harmonization of the study protocols (eligibility criteria, treatment strategies, outcome, start and end of follow-up, causal contrast) so that the studies target the same causal effect, 2) harmonization of the data analysis to estimate the causal effect, and 3) sensitivity analyses to investigate the impact of discrepancies that could not be accounted for in the harmonization process. To illustrate our approach, we compared estimates of the effect of immediate with deferred initiation of antiretroviral therapy in individuals positive for the human immunodeficiency virus from the Strategic Timing of Antiretroviral Therapy (START) randomized trial and the observational HIV-CAUSAL Collaboration.
ISSN:0002-9262
1476-6256
DOI:10.1093/aje/kwz100